The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: Towards a more effective strategy to improve clinical outcome in giant cell arteritis?

Rheumatology (United Kingdom)

Volumn 55, Issue 1, 2016, Pages 66-70

  Diamantopoulos, Andreas P ^a   Haugeberg, Glenn ^a,b   Lindland, Are ^c   Myklebust, Geirmund ^a  

^a Southern Norway Hospital Trust   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c Department of Ophthalmology   (Norway)

Author keywords

health economics; outcome measures; Temporal arteritis; ultrasonography; vasculitis

Indexed keywords

METHYLPREDNISOLONE;

AGED; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTICLE; BLOOD VESSEL BIOPSY; BLURRED VISION; CLASSIFICATION ALGORITHM; COLOR ULTRASOUND FLOWMETRY; COST EFFECTIVENESS ANALYSIS; DIPLOPIA; EARLY DIAGNOSIS; FEMALE; GIANT CELL ARTERITIS; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; REAL TIME ULTRASOUND SCANNER; TEMPORAL ARTERY; TRANSITIONAL BLINDNESS; VISUAL IMPAIRMENT;

EID: 84960087345     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev289     Document Type: Article

References (22)

1. Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
2. Haugeberg G, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 2000;27:2624-7.
3. González-Gay MA, García-Porrúa C, Llorca J et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 2000;79:283-92.
4. Salvarani C, Cimino L, Macchioni P et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005;53:293-7.
5. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002;80:355-67.
6. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098-103.
7. Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatr 2007;78:1255-9.
8. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998;125:521-6.
9. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
10. Muller S, Zalunardo MP, Hubner M et al. A fast-track program reduces complications and length of hospital stay after open colonic surgery. Gastroenterology 2009;136:842-7.
11. Winther SB, Foss OA, Wik TS et al. 1-year follow-up of 920 hip and knee arthroplasty patients after implementing fasttrack. Acta Orthop 2014;86:1-8.
12. Ratanakorn D, Keandoungchun J, Sittichanbuncha Y, Laothamatas J, Tegeler CH. Stroke fast track reduces time delay to neuroimaging and increases use of thrombolysis in an academic medical center in Thailand. J Neuroimaging 2012;22:53-7.
13. Olesen F, Hansen RP, Vedsted P. Delay in diagnosis: the experience in Denmark. Br J Cancer 2009;101 (Suppl 2):S5-8.
14. Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012;71:1921-3.
15. Ultrasound Versus Biopsy in Diagnosis of Giant Cell Arteritis (TABUL). 2010. http://clinicaltrials.gov/ct2/show/NCT00974883?term=gca&rank=1.
16. Norwegian Ministry of Finance. Inpatient days cost in the Norwegian Hospitals. 2013 [cited 2013]. http://www. regjeringen.no/en/dep/fin/Documents-and-publications/andre/Publications-in-English-or-translated-in/brev_stortinget/2013/sporsmal-nr-834-til-skriftlig-besvarelse. html?id=714876 (31 July 2015, date last accessed).
17. Diamantopoulos AP, Haugeberg G, Hetland H et al. The diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res 2014;66:113-9.
18. Patil P, Achilleos K, Williams M et al. 9. Outcomes and cost effectiveness analysis of fast track pathway in giant cell arteritis. Rheumatology 2014;53 (Suppl 2):i5-6.
19. Schmidt WA, Krause A, Schicke B, Kuchenbecker J, Gromnica-Ihle E. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology 2009;48:383-5.
20. Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996;35:1161-8.
21. Poller DN, van Wyk Q, Jeffrey MJ. The importance of skip lesions in temporal arteritis. J Clin Pathol 2000;53:137-9.
22. De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol 2015;42:119-25.